Nivolumab Gets Breakthrough Designation for Hodgkin's Lymphoma
BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.
3 Ways to Create Value-Oriented Healthcare
Focus on services' worth to combat soaring healthcare spending.
New Payment Models Could Motivate Providers to Cut Wasteful Services
The overuse of pricey medical technology and medication presents a complex challenge for policymakers, hospitals and doctors trying to reduce costs.
Necitumumab by Eli Lilly Improves OS in a Phase 3, First-Line Treatment of NSCLC
Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).
Lung Cancer Screening Could Cost Medicare Billions
Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.
For Medicaid Patients, Access To Primary-Care May Not Be As Advertised
Using mystery shoppers looking for access to health care, Public Health Seattle & King County has found troubling indications that access to primary-care providers may not be as advertised.
The University of Chicago Cancer Center Awarded Nearly 4 Million by the NCI
University of Chicago's Comprehensive Cancer Center received $3.9 million from the NCI as the Lead Academic Participating Site for the new NCTN initiative.
MedImmune and Incyte Announce Immuno-Oncology Collaboration
MedImmune and Incyte are planning the initiation of a collaborative Phase I/II study to test the efficacy of MedImmune's PD-L1 inhibitor MEDI4736 with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Aetna, Humana, UnitedHealthcare to Supply Healthcare Cost Data for New Transparency Tool
Three major insurers are partnering with a not-for-profit group to provide consumers with greater access to healthcare cost information, the group announced Wednesday morning.
NICE Prevents Use of Zytiga Prior to Chemotherapy
Britain's healthcare cost-effectiveness agency, NICE, has recommended against using Zytiga in chemotherapy-naive prostate cancer patients.
AJMC to Host 1st ACO Coalition Event to Focus On Improving Care Management
The American Journal of Managed Care will host the first gathering of its ACO and Emerging Healthcare Delivery Coalition this week in Baltimore, Md. The ACO Coalition aims to share best practices for setting up successful ACOs.
What Surge? Nation's Primary Care System Holding Up Well So Far Under Obamacare
The headlines were ominous: Good luck finding a doctor under Obamacare. Not enough doctors for newly insured. Obamacare, doctor shortage could crash health system.
Wasteful Services Cost Medicare Up to $8.5 Billion, Study Estimates
One in four Medicare patients got medical care at least once in 2009 that provided no benefit at a total cost of at least $1.9 billion, newly published research suggests.
CMS' Reported Nixing of End-to-End ICD-10 Test Irks Critics
The CMS has canceled its first scheduled round of end-to-end testing for ICD-10 in the wake of a recent, one-year reset of the compliance deadline to Oct. 1, 2015, according to knowledgeable sources.
Ethnicity and Socioeconomic Status Determine Breast Cancer Susceptibility
A study published in the journal Breast Cancer Research and Treatment identified increased incidence of triple negative breast cancer in black women compared to white women, while those with Asian heritage were found more susceptible to HER2-positive breast cancer.
ASCO Releases New Resources for Cancer Management in Obese Patients
ASCO today released new resources to help physicians manage the complications of obesity in patients with cancer and facilitate communication about the importance of weight management and making healthy lifestyle choices following a cancer diagnosis.
To Reduce Costs, Health Workers Move Toward More Contact with Patients
Many patients with chronic diseases now find themselves in contact with clinic-employed health coaches who nudge them to take their medications, eat right, be active and assume ownership of their health.
Redesigning and Revaluing HSA Plans
Amid two seemingly unrelated trends, the rise of high-deductible health plans and the growing prevalence and burden of chronic diseases, it may time to rethink the concept and regulation of preventive services, argue advocates of value-based insurance.
Obamacare Question: Ditch Employer Mandate?
A left-leaning think tank whose research is often taken seriously by backers of the health-care overhaul has published a paper suggesting the administration should scrap the health law's requirement that employers offer coverage or pay a penalty.
Sequenta's MRD Detection Test Predicts Post-Transplant Relapse and Survival in ALL
Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.
Taiho Oncology's Drug for Refractory Metastatic CRC Improves OS in Phase III Trials
Having met the primary endpoint of overall survival in it's Phase III trial of TAS-102 for refractory metastatic CRC, Taiho plans regulatory submissions.
Healthcare Providers' Trust in Payers 'Abominably Low'
A survey designed to measure the level of trust that hospital executives have in health insurance companies finds several factors that contribute to low scores, including the length of time it takes for claims to be paid, and the rates hospitals and physicians are paid.
In The Literature: Using a Patient's Immune Cells to Treat Metastatic Cholangiocarcinoma
Researchers identified tumor-infiltrating CD4+ T cells specific for a mutated antigen expressed by a tumor from a patient with metastatic cholangiocarcinoma. Infusion of this patient with an expanded-population, mutation-specific T cell resulted in tumor regression and stabilization of disease.